VIDEO: ANXV may improve vision in retinal vein occlusion
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, discusses a phase 2a study on ANXV in treatment-naive patients with retinal vein occlusion.
Singer said ANXV (Annexin Pharmaceuticals) is a first-in-class therapy that targets phosphatidylserine and blocks its downstream effects including retinal vein occlusion.
“Of the 10 out of 15 patients who finished follow-up, 60% had improved vision, and 40% had stable vision,” he said. “If we dig deeper in the improved vision category, essentially 60% of those were three-line gainers.”
Collapse
Singer M. First time results from proof of concept phase 2a study with ANXV in treatment naive patients with RVO. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Read more about
Click Here to Manage Email Alerts